Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma. - Wikidata - wikimedia - TriplyDB

Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

http://www.wikidata.org/entity/Q37672032

about

Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

http://www.wikidata.org/entity/Q37672032

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

@en

Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

@nl

type

label

Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

@en

Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

@nl

prefLabel

Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

@en

Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

@nl

P1433

Q37672032-6352EE4F-1901-4BF6-8649-DEBCDF982F36

P1476

Q37672032-DC70EE6C-AFF8-4AF4-A411-6A5159FB6812

P2093

Q37672032-0BF99DA2-A184-4271-B101-DB05B38F7956

Q37672032-244F7528-1E5C-4B8B-A342-9A3739BC8DF4

Q37672032-27F89144-4FC8-4DD1-B5CE-0DF6C315D9B5

Q37672032-545E20E0-9AAF-4EBC-89AF-46A64CFCCF8D

P2860

Q37672032-1BBE62B7-4EA1-4594-88E6-D56C3DD0FD06

Q37672032-1C605948-2105-48D3-9416-09A0E7DE50A6

Q37672032-2A83EFE0-C236-4684-9D58-799FF45D7F51

Q37672032-373204D6-5D6F-43ED-86E8-71A5F223E93D

Q37672032-4FCC5FC6-5831-44BE-A760-698B6179B48C

Q37672032-5D0872BA-C14B-4E5D-85E4-67A6FEF404B1

Q37672032-7D0580E0-FBDA-4D45-9595-F8F3FACF7204

Q37672032-7E13D619-E6C6-4981-99AC-3B05EC0D7CDC

Q37672032-8CEA3040-82D9-49F7-8EAF-40DE6F3A4D7E

Q37672032-91A979BE-16F6-4E86-A09B-01DC96C6585D

P304

Q37672032-0565780B-F32E-49C5-A301-8E13E66C554E

P31

Q37672032-193D5559-4E47-4778-987E-3E08810E4C47

P356

Q37672032-9752204A-FD13-419E-AE53-9E8ADE23A0BE

P433

Q37672032-06805804-DDFA-4F05-AA54-41681EEEC6D6

P478

Q37672032-8E5FA689-7FA1-48BF-AECF-B7A4E102FCE8

P577

Q37672032-FB673A4C-E2CD-4EA2-8033-94D2197E869C

P698

Q37672032-7359D6B3-C685-4567-8C74-DBBA387D72A2

P932

Q37672032-1D1EC6AA-F803-4B81-AF75-E5B6DC3A00C7

P356

P1433

Current Oncology

P1476

Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

@en

P2093

G S Zaric

http://www.w3.org/2001/XMLSchema#string

J Mangel

http://www.w3.org/2001/XMLSchema#string

M A Begen

http://www.w3.org/2001/XMLSchema#string

V Babashov

http://www.w3.org/2001/XMLSchema#string

P2860

Health-related quality of life in Hodgkin lymphoma: a systematic review

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease.

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.

Cost effectiveness of treatment options in advanced breast cancer in the UK.

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

P304

e6-e14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.24.3369

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28270727

http://www.w3.org/2001/XMLSchema#string

P932

5330640

http://www.w3.org/2001/XMLSchema#string